Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.44 USD | -1.53% | -8.26% | -13.98% |
May. 09 | UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating | MT |
May. 08 | Transcript : REGENXBIO Inc., Q1 2024 Earnings Call, May 08, 2024 |
Evolution of the average Target Price on REGENXBIO Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering REGENXBIO Inc.
UBS | |
HC Wainwright | |
RBC Capital Markets | |
Baird | |
Leerink Partners | |
Wedbush | |
Stifel Nicolaus | |
Morgan Stanley | |
Chardan Research | |
SVB Securities LLC | |
Berenberg Bank | |
SVB Leerink | |
Chardan | |
Barclays |
EPS Revisions
- Stock Market
- Equities
- RGNX Stock
- Consensus REGENXBIO Inc.